Navitoclax
- Generic Name
- Navitoclax
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C47H55ClF3N5O6S3
- CAS Number
- 923564-51-6
- Unique Ingredient Identifier
- XKJ5VVK2WD
- Background
Navitoclax has been used in trials studying the treatment and basic science of Solid Tumors, Non-Hodgkin's Lymphoma, EGFR Activating Mutation, Chronic Lymphoid Leukemia, and Hematological Malignancies, among others.
...
- Associated Conditions
- -
- Associated Therapies
- -
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2023-05-18
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 40
- Registration Number
- NCT05864742
- Locations
- 🇦🇺
Flinders Medical Centre, Bedford Park, South Australia, Australia
🇦🇺Peter MacCallum Cancer Centre, Parkville, Victoria, Australia
🇦🇺Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Conditions
- Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentAcute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Registration Number
- NCT05740449
- Locations
- 🇳🇱
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Thomas Jefferson University
- Target Recruit Count
- 6
- Registration Number
- NCT05564650
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Jacqueline Garcia, MD
- Target Recruit Count
- 16
- Registration Number
- NCT05455294
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
- Conditions
- Interventions
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 36
- Registration Number
- NCT05358639
- Locations
- 🇨🇦
Sunnybrook Research Institute/Odette Cancer Centre, Toronto, Ontario, Canada
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇨🇦CHUM, Montreal, Quebec, Canada
Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax
- Conditions
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 17
- Registration Number
- NCT05222984
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients With Relapsed or Refractory ALL or LL
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Kathleen Ludwig
- Registration Number
- NCT05215405
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
- Conditions
- Interventions
- Drug: VenetoclaxDrug: NavitoclaxDrug: DexamethasoneDrug: VincristineDrug: Calaspargase PegolDrug: DasatinibDrug: LeucovorinDrug: CytarabineDrug: Intrathecal TriplesBiological: BlinatumomabDrug: PegaspargaseDrug: MethotrexateDrug: Erwinia asparaginaseDrug: MercaptopurineDrug: CyclophosphamideDrug: EtoposideRadiation: Radiation
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05192889
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL
- Conditions
- Interventions
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Israeli Medical Association
- Target Recruit Count
- 48
- Registration Number
- NCT05054465
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
🇮🇱Soroka Medical Center, Be'er Sheva, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1
- Registration Number
- NCT04480086
- Locations
- 🇺🇸
Stony Brook University Hospital /ID# 222653, Stony Brook, New York, United States
🇰🇷Inje University Busan Paik Hospital /ID# 224043, Busan, Korea, Republic of
🇺🇸UC Health - Cincinnati /ID# 224079, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.